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Carcinoma stomach remains a leading cause of cancer death
worldwide and most patients present with locally advanced disease. The
recurrence rates following curative surgery for locally advanced disease
has been consistently high and has been attributed to low volume
peritoneal metastasis even at the time of diagnosis which was not picked
up by conventional imaging modalities.
Diagnostic laparoscopy has been advocated as a way of improving
staging and has been reported to be superior compared to Endo
Ultrasound or Computed Tomography.
The benefits of staging laparoscopy are:
a) Its ability to detect distant metastases especially small volume
peritoneal metastasis by direct visualization under magnification which
are usually missed by conventional imaging, thereby protecting the
patient from an unnecessary laparotomy.
b) Laparoscopy allows pathologic confirmation of nodal status, which
could aid prognostication and help define radiation fields.
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c) Providing tissue samples to assess the prognostic ability of
molecular markers.






Epidemiology of gastric cancer
Gastric cancer affects more than 8,00,000 new individuals world-
wide each year. Over the past few decades, there has been a drastic
decline in the rates of stomach cancer in many developed countries.
Interestingly, this decline is only limited to the incidence of distal gastric
cancers. However, the occurrence of proximal gastric and gastro-
oesophageal junction cancers is actually rising.
In India, the incidence of gastric cancer is showing a more gradual
decline in all the population based tumour registries. Data from the
country’s northeastern registries however continues to show some very
high incidences.
Mortality rates from gastric cancer approach incidence rates and




The stomach has a fundus, a body and a pylorus which have specific
histologic features.
• The cardia mainly has goblet cells, which secrete mucin.
• The body contains mucin cells, chief or zymogenic cells, and
parietal or oxyntic cells.
• The pylorus contains G cells which secrete gastrin.
Histologically, the stomach wall has 5 layers - the mucosa, the
submucosa, the muscularis layer, subserosa and the serosa.
Relations
• The stomach is related superiorly by the diaphragm and left lobe
of liver;
• Anteriorly by the abdominal wall and
• Below by the transverse colon, mesocolon, and greater omentum.
• Posteriorly and to the left are the spleen, pancreas, left adrenal
gland, left kidney, and splenic flexure of the colon.
Cancers arising from the proximal stomach may directly involve the
splenic hilum/ spleen, diaphragm, left lateral segment of the liver and tail
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of pancreas, whereas more distal tumors may invade the transverse colon
or the pancreatic head.
According to the Japanese classification system, gastric cancer is
classified into those involving the antrum or lower part (L) – 40%, the
body or middle part (M) – 40% and the upper part (U) – 15%.
Involvement of more than one part of the organ (designated as LM or
UM or LMU etc) occurs in 10% of patients.
Blood supply
The blood supply to the stomach is extensive and is based on vessels
arising from the celiac axis (Fig. 1). The right gastric artery from the
hepatic artery, and the left gastric artery, a direct branch of the celiac
axis, course along the lesser curvature. Along the greater curvature are
the right gastroepiploic artery, which originates from the gastroduodenal
artery at the inferior border of the proximal duodenum, and the left
gastroepiploic artery, branching from the splenic artery laterally. The
short gastric arteries (vasa brevia) arise directly from the splenic artery
and make a relatively small contribution to the blood supply to the
proximal portion of the stomach.
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The preservation of any of these vessels in the course of a subtotal
gastrectomy for carcinoma is not necessary and the most proximal few
centimeters of remaining stomach are well supplied by collateral flow
from the lower segmental esophageal arcade and the inferior phrenic
vessels. The rich submucosal blood supply of the stomach is an important
factor in its ability to heal rapidly and produce a low-incidence of
anastomotic disruption.
Fig 1: Arterial supply of stomach
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The venous supply of the stomach tends to parallel the arterial
supply. The venous efflux ultimately passes the portal venous system and
is reflected in the fact that the liver is a primary site for distant metastatic
spread.
Lymphatic drainage
The lymphatic drainage of the stomach is extensive, and distinct
anatomic groups of first echelon perigastric lymph nodes have been
defined according to their relationship to the stomach and its blood
supply: right and left cardiac, lesser and greater curvature and the supra
and subpyloric nodes. and gastroepiploic nodes, and along the lesser
curvature are the suprapyloric and the lesser curvature lymph nodes.
The second echelon (extraperigastric) nodes include the common
hepatic, left gastric, splenic hilum and splenic artery lymphatics, which
drain into the celiac and periaortic lymphatics. Proximally are the lower
esophageal lymph nodes;
Extensive spread of gastric cancer along the intrathoracic lymphatics
may be manifested clinically by a metastatic lymph node in the left
supraclavicular fossa (Virchow's node) or left axilla (Irish's node). As the
submucosal lymphatic supply of the stomach becomes extensively
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involved with tumor, other routes of lymphatic drainage may be
recruited. Tumor spread can occur along the falciform ligament to the
lymphatics in the hepatoduodenal ligament resulting in subcutaneous
periumbilical tumor deposits known as Sister Mary Joseph's nodes.
The regional lymph nodes are grouped into stations numbered as in
Fig.2 as per the Japanese system. They classified into three groups based
upon the location of the primary tumor.
18
Fig 2: Lymph node stations of stomach
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Pathology and Tumor Biology
Adenocarcinoma constitutes approximately 95% of all malignant
neoplasms of stomach. Other malignancies, which can rarely occur, are
squamous cell carcinomas, leiomyosarcoma, adenoacanthoma, carcinoid
tumors and lymphomas. The differentiation between adenocarcinoma and
lymphoma can sometimes be difficult but is essential because staging,
treatment, and prognosis are different for each disease.
Morphological classification
Early Gastric cancer is classified by Japanese system into three
groups (Fig 3).
Advanced gastric cancer is morphologically classified using the
Borrmann classification (Fig.4) depending on the macroscopic
appearance.
Fig 3: Japanese classification of Early Gastric cancer
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Fig 4: Borrmann’s classification
The macroscopic type of the primary neoplasm should be reported
along with the T stage.
Ming has proposed a histomorphologic staging system that divides
gastric cancer into either a prognostically favorable expansive type or a
poor prognosis infiltrating type. Based on an analysis of 171 gastric
cancers, the expansive-type tumors were uniformly polypoid or
superficial on gross appearance, whereas the infiltrative tumors were
almost always diffuse. Grossly ulcerated lesions were equally divided
between the expanding or infiltrative forms.
The commonly used Lauren’s DIO system classifies gastric cancers
into intestinal type (53%), diffuse type (33%), and unclassified (14%).
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The intestinal type is associated with chronic atrophic gastritis, severe
intestinal metaplasia, and dysplasia and tends to be less aggressive than
the diffuse type. The diffuse type of gastric cancer is more likely to be
poorly differentiated and is associated with younger patients and
proximal tumors.
Broder's classification of gastric cancer grades tumors histologically
from 1 (well- differentiated) to 4 (anaplastic). This correlates with the
Bormann’s classification with ninety percent of protruding or superficial
cancers being well differentiated (Broder's grade 1) and almost half of all
ulcerated tumors being poorly differentiated or diffusely infiltrating
(Broder's grades 3 and 4).
Oesophagogastric junction cancers are classified using the Siewert's
classification, into three distinct types:
Type 1: Adenocarcinoma of the distal esophagus, between 1 to 5 cm
from the anatomic cardia. it commonly arises from Barrett's esophagus
and can involve the esophagogastric junction from above.
Type II: Adenocarcinoma of the cardia, occurring in the region
between 1 cm proximal and 2 cm distal to the anatomic cardia.
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Type III: Adenocarcinoma of the proximal stomach, 2- 5 cm from
the anatomic cardia.
The classification is based on morphology and the anatomic location
of the epicenter of the tumor as discerned by barium swallow, upper GI
scopy, CT, and intraoperative findings.
The Siewert's classification has important therapeutic implications.
Lymphangiographic studies have shown that the lymphatic pathways
from the lower oesophagus (type 1) pass both cephalad (into the
mediastinum) and caudad (toward the celiac axis). In contrast, the
lymphatic drainage from the cardia and subcardiac regions (types II and
III) is toward the celiac axis, splenic hilum, and para-aortic nodes. Type I
tumors require an oesophagectomy, whereas types II and III tumors can
be treated by transabdominal extended gastrectomy (resection of the
stomach and distal intra-abdominal esophagus).
Patterns of Spread
The spread of stomach cancer can occur by several modes including
local infiltration into the adjacent structures, lymphatic and peritoneal
metastases, and by distant hematogenous spread. The cancer initially
grows by penetration into the gastric wall and infiltrating intramurally -
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often through intramural lymphatics or in the subserosal layers, thus
progressively involving an increasing thickness and percentage of the
stomach respectively.
Tumor penetration through the gastric serosa, with consequent risk
of tumor invasion into adjacent structures or peritoneal spread and
involvement of lymphatics have therapeutic impact. Local extension can
also occur into the esophagus or the duodenum. Duodenal extension is
principally through the muscular layer by direct infiltration and through
the subserosal lymphatics, but is not generally of great extent. Extension
into the esophagus occurs primarily through the submucosal lymphatics.
Lymph node metastases are found in up to 18% of pT1 lesions after
R0 resection increasing to 60% in pT2 lesions. The highest incidence of
lymph node metastases are seen in diffusely infiltrating tumors. Tumors
located at the gastro-oesophageal junction also have a higher incidence
compared to other sites. The pattern of lymph node involvement is
dictated by the location of the primary tumour.
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Clinical Presentation and Pretreatment Evaluation
Signs and Symptoms
Carcinoma stomach usually presents with only vague symptoms
such as weight loss, anorexia, fatigue, or epigastric discomfort. Hence,
most patients present with advanced-stage disease.
• Most of the patients have more than 10% weight loss at
presentation. Patients with significant weight loss had a
significantly shorter survival than those without weight loss.
• Dysphagia may be indicative of a cardiac location with extension
through the gastro- oesophageal junction.
• Early satiety may be present in diffusely infiltrative tumors as a
result of loss of distensibility of the stomach wall.
• Persistent vomiting is indicative of pyloric obstruction due to
antral growth.
• Significant gastrointestinal bleeding while uncommon occurs
approximately 10% to 15% of patients. Melena however is a
much more common symptom. Anaemia due to persistent
microscopic/ gross bleed is a very common sign.
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• Ascites, jaundice, or a palpable mass indicates locally advanced
or metastatic disease. Due to proximity of the transverse colon, it
may be infiltrated by gastric malignancy causing a gastrocolic
fistula and obstruction.
• Peritoneal seedling can result in bilateral large ovarian
secondaries (Krukenberg's tumor) or pelvic deposits (Blumer's
shelf) as evident by pelvic or rectal examination.
• Nodular metastases in the subcutaneous tissue around the
umbilicus (Sister Mary joseph’s nodule) or in peripheral lymph
nodes represent areas in which a tissue diagnosis can be
established with minimal morbidity.
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Fig 5: Umbilical nodule (Sister Mary joseph’s nodule)
Fig 6: Virchow’s node
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Screening
Mass screening programs for gastric cancer have been most
successful in high-risk areas, especially in Japan (1). A variety of
screening tests have been studied in Japanese patients, with a sensitivity
and specificity of approximately 90%. Screening typically includes the
use of double-contrast barium radiographs or upper endoscopy (2).
Pretreatment Staging
Tumor Markers-
The carcinoembryonic antigen (CEA) level is elevated in
approximately one third of patients with primary gastric cancer. Though
the sensitivity of CEA as a marker of gastric cancer is low, when
elevated, it generally correlates with stage.
Combining CEA with other markers, such as the sialylated Lewis
antigens CA 19-9 or CA 50, can increase the sensitivity compared with
CEA alone (3).
Endoscopy-
Endoscopy is considered to be the best method to diagnose gastric
cancer. It directly visualizes the gastric mucosa and helps define the type
of gastric cancer, allows assessment of the proximal and distal extent of
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disease, assess distensibility of the stomach walls, helps detect satellite
lesions and allows biopsy of tissue for a histologic diagnosis.
EUS (2) is used to further stage previously diagnosed tumors. It has
the capability to evaluate the deeper layers of the gastric wall to help
define the T stage of the tumor and provide information on the
morphologic status of surrounding lymph nodes. EUS has an accuracy of
up to 90% for T staging of gastric tumors and 75% for N staging; these
rates are higher than those for preoperative computed tomography (CT)
scans.EUS may also be helpful in identifying early diffuse-type gastric
carcinoma lesions that might be otherwise overlooked.
Fig 7: Endoultrasound – tumour invading muscularis
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Computed Tomography-
Once gastric cancer is suspected, CT of the abdomen and pelvis is
an important part of the staging evaluation. Patients with Siewert's type I
or II tumors (see below) should also undergo a chest CT. CT is useful for
noninvasive assessment of perigastric lymphadenopathy, peritoneal
disease, and intra-abdominal visceral (primary liver) metastatic disease
and for estimation of the degree of tumor penetration through the gastric
wall. With modern multiphase, multidetector spiral CT imaging, there is
increased accuracy in the assessment of extragastric disease and mural
penetration (particularly for T2 and greater tumors). The accuracy of CT
assessment of tumor location and T stage can be enhanced over that of
conventional helical CT by use of water as an oral contrast agent (helical
hydro-CT).
Fig 8: CECT showing an early gastric cancer
30
Fig 9: CECT showing a locally advanced gastric cancer
Fig 10: CECT of a T2 lesion of stomach
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Positron Emission Tomography(4)-
The role of whole body 2-[18F]-fluoro-2-deoxyglucose (FDG)
positron emission tomography (PET) in the management of gastric cancer
is currently uncertain. A significant proportion of primary tumors are not
FDG avid. This may be in part due to the fact that the glucose transporter-
1, an important transporter of FDG into tumor cells, is rarely present is
common subtypes of gastric carcinoma, including signet ring cell
carcinoma and mucinous adenocarcinoma. FDG-PET CT scans does not
help identify occult peritoneal disease, though it does detect
extraperitoneal M1 disease.
Fig 11: Positron Emission Tomography
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Laparoscopy -
Staging laparoscopy is an integral part of the pretreatment staging
evaluation of patients felt to have localized gastric cancer after initial
helical CT assessment. This is because the sensitivity of CT for detection
of extragastric disease declines with the size of metastases.
Laparoscopy allows for direct inspection of the peritoneal and
visceral surfaces for detection of CT-occult small volume metastases.
Staging laparoscopy also allows for assessment of peritoneal cytology
and intraperitoneal evaluation with adjunctive diagnostic techniques such
as laparoscopic ultrasound. The rate of detection of CT-occult M1 disease
by laparoscopy ranges from 13% to 37% and is dependent on the quality
of CT scanning and interpretation (5,6,7). However, the extent of
laparoscopic evaluation and the use of laparoscopic ultrasound are
unresolved staging issues (8,9).
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Fig12: Diagnostic laparoscopy
Staging, Classification, and Prognosis
Uniform and accurate staging of cancer is essential to meaningfully
predict prognosis and assess outcome. For patients with surgically treated
gastric adenocarcinoma, both pathologic staging (International Union
Against Cancer [UICC] or Japanese system) and classification of the
completeness of resection (R) should be done (10).
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In addition, the histopathologic grade and type and the peritoneal
lavage cytology status should be recorded. The latter is important because
the presence of free peritoneal cancer cells has been shown by a number
of investigators to carry a prognosis comparable to that of visceral
metastatic disease.
The UICC TNM staging system for gastric cancer is outlined below
Table 1. In the AJCC/UICC staging system, tumor (T) stage is
determined by depth of tumor invasion into the gastric wall and extension
into adjacent structures. The relationship between T stage and survival is
well defined.
Nodal stage (N) is based on the number of involved lymph nodes, a
criterion that may predict outcome more accurately than the location of
involved lymph nodes (12,13). The use of numerical thresholds for nodal
classification has become increasingly more accepted. The threshold
approach is based on observations that survival decreases as the number
of metastatic lymph nodes increases (14,15). Given the reliance on
numerical thresholds for nodal staging, it is extremely important that
surgeons and pathologists work together to ensure that adequate numbers
of lymph nodes are retrieved and examined (16,17).
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Table 1: UICC staging of gastric cancer
Ratio-based lymph node classification ratio of metastatic to
uninvolved lymph nodes –(RML) may minimize the confounding effects
of regional variations in the extent of lymphadenectomy and in
pathologic evaluation of the lymphadenectomy specimen on lymph node
staging and thereby reduce the impact of stage migration. RML was
found to be an independent prognostic factor for survival and reduced the
frequency of stage migration (18).
Japanese Staging System (19)
The most recent Japanese Classification for Gastric Carcinoma was
published in 1998. The Japanese classification and staging system is more
detailed than the AJCC/UICC staging system and places more emphasis
on the distinction between clinical, surgical, pathologic, and final staging
(prefixes c, s, p, and f respectively) (Table 2).
In addition to lymph node compartments, it also reports presence or
absence of hepatic (H), distant metastases (M), peritoneal metastases (P)
and peritoneal cytology (CY) in addition to proximal and distal margins
(PM and DM respectively), For example, a surgically treated and staged
patient with locally advanced, nonmetastatic gastric cancer might be
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staged as pT3, pN2, sH0, sM0, f stage IIIB (where H0 denotes no hepatic
metastases and the f prefix denotes final clinicopathologic stage).
Table 2: Principles of recording
Similar to the UICC staging system, primary tumor (T) stage in the
Japanese system is based on the depth of invasion and extension to
adjacent structures, as outlined in Table 4. However, the assignment of
lymph node (N) stage involves much more rigorous pathologic
assessment than is required for UICC staging. As mentioned earlier in the
section on lymphatic spread, the Japanese system extensively classifies
18 lymph node regions into four N categories depending on their
relationship to the primary tumor and anatomic location.
The Japanese staging system (table 3) also includes elements not
included in the AJCC/UICC system. These are macroscopic description
of the tumor (early gastric cancer subtype or Borrmann type for more
advanced tumors), extent of peritoneal metastases (classified as P0-1),
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extent of hepatic metastases (H0-1), and peritoneal cytology findings
(CY0-1). The comprehensive c, s, p and f prefix system used in the
Japanese system provides a succinct and accurate summary of an
individual patient's extent of disease.
Table 3: Japanese Gastric cancer association staging system
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Resection Classification
The R classification system indicates the amount of residual disease
left after tumor resection (20). R0 indicates no gross or microscopic
residual disease; R1 indicates microscopic residual disease, and R2
signifies gross residual disease. The R classification has implications for
individual patient care and clinical research. Surgeons should wait for the
final pathology results before completing their operative summaries so
that patient records include the R classification for the gastrectomy.
Results of clinical trials that include surgery should include information
on R status.
Predicting Individual Patient Prognosis
Kattan et al.(21) have developed a nomogram for estimating 5-year
disease-specific survival using established prognostic factors derived
from a population of 1,039 gastric cancer patients treated by R0 surgical
resection at a single institution (www. nomograms.org).
Clinicopathologic factors incorporated in the nomogram include patient
age and gender, primary tumor site, Lauran classification, tumor size and
depth, and the numbers of positive and negative lymph nodes. This tool
may be useful for individual patient counseling, follow- up scheduling,
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and clinical trial eligibility assessment and is available for personal hand-
held computer devices at www.nomograms.org.
Treatment of Early gastric cancer (Stage I)
Treatment Options for Early gastric cancer include Endoscopic
mucosal resection (EMR), Limited surgical resection and Gastrectomy.
Endoscopic mucosal resection (EMR) is offered only to patients with low
lymph node metastatic potential i.e well differentiated, < 3 cm, superficial
Type II a or Type II c lesions in conducive location. It can be done by
several methods - Saline lift technique or Cap suction / cut and ligate
method. The criteria for limited surgical resection is the same as for
EMR, but this procedure is done for difficult locations. For poorly
differentiated tumours, size > 3 cm with penetration to submucosa and
beyond, gastrectomy should be done. However, if the patient with EGC is
unfit for gastrectomy, EMR can be done.
Fig 13: EMR – Lift and snare technique
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Fig 14: EMR – Cap technique
Fig 15: EMR - Multiband mucosectomy technique
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There is no consensus regarding the extent of lymphadenectomy in
EGC. D 0 dissection with lymph node sampling, sentinel node sampling
are being explored. However, Dissection of group 1 lymph nodes seems
to be the standard at present.
Treatment of locally advanced gastric cancer (Stage II and III)
Surgery (22)
Poor performance status, presence of supraclavicular or axillary
nodes, periumbilical nodules, malignant ascitis, peritoneal and hepatic
metastases are indicators of inoperability.
Surgical R0 resection is the cornerstone of treatment for
patients with localized gastric cancer. Three features need to be
emphasized when discussing gastrectomy for cancer. These include
a. Omental bursectomy
b. Extent of gastrectomy
c. Extent of lymphadenectomy
Extent of gastrectomy:
The extent of gastrectomy required for satisfactory primary tumor
treatment depends on
a): the gross and microscopic status of surgical margins and
b): on the extent/ level of lymphadenectomy required.
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For most clinical situations, a 5-cm grossly negative margin around
the tumor and microscopically negative surgical margins (R0) are the
treatment goals. When the general oncologic goal of an R0 resection can
be achieved by partial gastrectomy, it is preferred over total gastrectomy
to minimize the risks of specific sequelae of total gastrectomy such as
early satiety, weight loss, and the need for vitamin B12 supplementation.
Many surgeons advocate a transabdominal resection of the lower
esophagus and proximal stomach or total gastrectomy for a Siewert's
types II or III cancer . Surgeons trained in thoracic surgery have
frequently advocated a combined abdominal and thoracic procedure
(often termed oesophagogastrectomy) with an intrathoracic or cervical
anastomosis between the proximal esophagus and the distal stomach or a
procedure termed transhiatal (or blunt) oesophagectomy (THE), which
involves resection of the esophagus and oesophagogastric junction with
mediastinal dissection performed in a blunt fashion through the
esophageal hiatus of the diaphragm.
Until additional RCTs are performed, the surgical approach to these
patients should be individualized and determined surgeon factors
(training and experience), patient factors (age, comorbidity, and
performance status), and tumor factors (pretreatment T and N stage).
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In addition, for cancers at all sites, the extent of gastric resection will also
be guided by the extent of devascularisation of the stomach caused by the
lymphadenectomy performed.
Extent of Lymphadenectomy
The extent of lymphadenectomy depends on three issues: a): the
frequency of involvement of lymph nodes at specific stations based on
the location of the primary cancer. b): staging removal and
histopathologic analysis of an adequate number of lymph nodes that will
predict with accuracy the extent of lymph node and distant metastases. c):
possibility of some forms of lymphadenectomy being therapeutic for
patients with gastric cancer.
The number of pathologically positive lymph nodes is of prognostic
significance and removal and pathologic analysis of at least 15 lymph
nodes is required for adequate pathologic staging which is reflected in the
UICC staging rules for gastric cancer. Multidisciplinary approach
mandates 1: surgeons perform an adequate lymphadenectomy, and 2:
pathologists retrieve and examine at least 16 lymph nodes to provide
optimal pathologic staging.
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The possible therapeutic benefit of extended lymph node dissection
has been studied in randomized clinical trials (23,24,25,26,27) There are
in addition reports from retrospective and non-randomised studies
involving over 5000 patients from Japan. Extended lymph node
dissections (D2) improve disease specific survival and locoregional
control. This also carries an increased risk for postoperative mortality,
morbidity and reoperation. With the acceptance of the a safer, spleen-
preserving D2 resection technique in high-volume centres, D2
lymphadenectomy is the recommended surgical approach for patients
with resectable (curable) gastric cancer (28).
Extended gastric resections (adjacent organs):
En-bloc resection of the transverse colon if the colon or adjacent
mesocolon is involved adds little to post operative morbidity and
mortality. It improves local disease control and quality of life and might
impact positively on survival. Routine distal pancreatectomy and
splenectomy as part of D2 dissection for proximal cancer does not
improve survival. On the other hand they have added to operative
morbidity, early surgical mortality and impacted negatively on long term
survival (29). Pancreatic and splenic resections are justified only when
there is direct tumour infiltration.
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Individualized Assessments of Lymph Node Involvement
Since extended lymphadenectomy carries an increased risk of
morbidity and mortality, attention has focused on methods of individual
assessment of risk of lymphatic spread. These techniques offer the
possibility of tailoring surgical therapy for an individual patient. At
present three approaches to individual nodal risk assessment have been
evaluated: computer modeling, preoperative endoscopic injection, and
sentinel lymph node biopsy. These methods are investigational currently.
Impact of high surgical volume on outcomes.
As in other surgical procedures, a clear relationship has been
demonstrated between institutional gastrectomy volume and perioperative
mortality rates. Gastrectomy at high- volume centers was associated with
the lowest surgical mortality, shortest duration of hospital stay and the
lowest readmission rates.
The variations in gastrectomy related mortality rates may be related
in part to surgeon training and experience with the procedure (30,31,32).
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Outcome in Japan Versus Western Countries
Stage-stratified survival rates for gastric adenocarcinoma are higher
in Japan than in most Western countries. The better-prognosis intestinal-
type (Lauran classification25) tumors (due to a higher incidence of H.
pylori infection and atrophic gastritis) are seen more commonly in Japan,
whereas the diffuse-type cancers that are associated with a poorer
prognosis are more frequent in Western series. Poorer-prognosis proximal
gastric cancers are less frequent in Japanese than in Western populations
(33) and the increase in proximal gastric cancers observed in the West
has not been observed in Japanese populations (34).
Regional differences in the diagnostic criteria for EGC also may
contribute to regional differences in observed outcome. In Japan, gastric
carcinoma is diagnosed based on its structural and cytologic features
without consideration of invasion of the lamina propria. In contrast,
Western pathologists consider invasion of the lamina propria to be an
essential element of the diagnosis of carcinoma (35,36). As a
consequence, unequivocally neoplastic noninvasive lesions are classified
as carcinoma in Japan but as dysplasia by Western pathologists.
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Stage migration is a well-documented factor contributing to the stage-
specific differences in outcome between Japanese and Western patients
(37). Widespread use of extensive D2 or D3 lymphadenectomy combined
with rigorous pathologic assessment of the lymphadenectomy specimen
in Japan results in more accurate stage assignment of Japanese patients.
This leads to secondary stage migration and improvement in stage-
specific survival without improvement in overall survival.
In addition, genetic, environmental, and biologic differences may also
contribute to the better survival of Japanese patients (38).
Technical points in performing a gastrectomy and D2 dissection (33)
Once distant metastases have been ruled out by laparoscopy, a
bilateral subcostal incision or a midline abdominal incision can be used to
gain exposure to the upper abdomen. The peritoneal cavity is examined
again and peritoneal fluid/ wash sample is collected for cytology. The
stomach should be inspected to assess the location and extent of tumor.
The size and location of the primary tumor dictate the extent of gastric
resection.
A D2 lymphadenectomy sparing the spleen and pancreas can be
done safely and provides an adequate specimen for surgical and
pathologic staging. This procedure should only be performed by or with
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an experienced surgeon.
The D2 subtotal gastrectomy commences with mobilization of the
greater omentum by incising the fourth layer of the greater omentum
along its attachment with the transverse colon (Fig 5).
This leads to the potential space between the third and fourth layers
of omental bursa on the transverse mesocolon along the upper border of
the colon, the middle colic vessels are left behind on the fourth layer.
This plane is developed down to the head of the pancreas where the
infrapyloric lymph nodes are dissected, and the origin of the right
gastroepiploic artery and vein ligated.
With a combination of blunt and sharp dissection, the plane of
dissection continues on to the anterior surface of the pancreas, extending
to the level of the common hepatic and splenic arteries. This maneuver
provides protection against serosal spread of tumor to the lesser sac
peritoneal surface.
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Fig 16: Showing line of dissection for omental bursectomy
The right gastric artery is ligated. At this point, the duodenum is
divided distal to the pylorus.
The stomach and omentum are then reflected cephalad. The
gastrohepatic ligament is divided close to the liver up to the gastro-
oesophageal junction. Dissection is then continued on the hepatic artery
toward the celiac axis. Once near the celiac axis, the lymph node bearing
tissue is dissected until the left gastric artery is visualized and can be
divided at its origin. During this process the coronary vein is also ligated.
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The proximal peritoneal attachments of the stomach and distal
esophagus can then be incised, and the proximal extent of resection is
chosen.
For tumors of the mid- and proximal stomach, dissection of the
lymph nodes along the splenic artery and splenic hilum is important. This
is not indicated for antral tumors.
The stomach is then divided 5 cm proximal to the tumor, which
dictates the extent of gastric resection. Despite the fact that the entire
blood supply of the stomach has been interrupted, a cuff of proximal
stomach invariably shows good vascularization from the feeding distal
esophageal arcade.
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It is safer to anastomose jejunum to stomach versus esophagus
because of the technical ease and excellent healing. Reconstruction using
a variety of techniques has been described.
Fig 17: Subtotal gastrectomy with Gastrojejunostomy
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Fig 18: A Total gastrectomy done for proximal gastric cancers following
which reconstruction is done by a Roux-en-y esophago-jejunostomy
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Adjuvant Therapy
The high risk for recurrence with surgery alone for advanced
resectable gastric cancer has led to extensive investigation of the use of
postoperative adjuvant, and more recently, perioperative systemic
therapy.
The term adjuvant therapy is best used to describe additional
treatment in an attempt to increase cure rates in patients who have already
undergone an R0 resection. The term perioperative chemotherapy (or
neoadjuvant chemotherapy) involves the use of systemic treatment before
definitive, potentially curative surgery.
Adjuvant therapy should commence as soon after operation as is
practical. Preclinical studies have shown a rapid increase in cell growth
of metastatic lesions after a primary tumor has been removed due to a
decline in circulating factors that block angiogenesis or other cell cycle
promoters. Neoadjuvant chemotherapy is thus an attractive concept for
patients with advanced gastric cancer, with a dual goal of decreasing the
stage/ volume of the primary tumor thus allowing a higher rate of R0
resections, and early treatment of micrometastatic disease.
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Adjuvant Postoperative Systemic Therapy
The results of most trials conducted till date do not show any benefit
for postoperative multiagent chemotherapy. Most of these have been
underpowered. Five meta-analysis (39,40,41,42) published till date have
indicated modest benefits of about 4%. However these did not analyse
individual data. Trials with large number of patients will be needed
before any recommendations can be made.
The most active agents seem to be 5 FU and its derivatives, cis-
platin, oxaliplatin, the anthracyclines doxorubicin and epirubicin and the
taxanes. Immunochemotherapy using either protein-bound
polysaccharide (PSK) or a Streptococcus pyrogenes preparation, OK432
has been tried with little benefit (43). More recently, trastuzumab has
been approved for adjuvant therapy along with chemotherapy in Her2neu
positive gastric cancers (44).
Adjuvant Intraperitoneal Chemotherapy (45)
Peritoneal recurrence is a common failure occurring in patients with
gastric cancer. The rationale for the use of intraperitoneal treatment is
based on the pharmacokinetic observation that drug concentrations within
the peritoneal cavity after intraperitoneal administration are much higher
than those achievable intravenously or orally. In ovarian cancer, a small
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but statistically and clinically significant advantage in survival has been
reported in large-scale trials for women who received at least a portion of
their therapy delivered intraperitoneally. While preclinical models in
gastric cancer support this observation, no definitive conclusions can yet
be drawn regarding the effectiveness of intraperitoneal postoperative
chemotherapy in this setting. Most centres report intraperitoneal
chemotherapy using either heated solutions (continuous hyperthermic
peritoneal perfusion, or CHIP) or nonhyperthermic treatment given either
immediately or instituted within several days of resection through
intraperitoneal catheters place at the time of surgery.
Neoadjuvant Chemotherapy
The landmark MAGIC trial (46) demonstrated an advantage of
systemic treatment plus operation when compared to operation alone.
There was a shift to an earlier stage overall in patients receiving
perioperative chemotherapy, as well as an improved R0 resection rate.
With a median follow-up of 4 years, there was a significant improvement
both in disease- free and in overall survival for patients receiving
perioperative chemotherapy: 5-year survival rate was 36% for those
receiving chemotherapy and 23% for those receiving surgery alone (HR
0.75; 95% CI, 0.6 to 0.9; P = .009).
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Adjuvant Radiation and Chemoradiation Therapy
Several studies have demonstrated a benefit of adjuvant
chemoradiation for both overall survival and locoregional disease control
(47,48). These have however not had rigid control over the surgical
procedure. There is an understanding that chemoradiation probably
offsets the adverse effects of inadequate surgery. Studies that plan to
include the type of surgery before randomization will be needed to settle
this issue. Radiation therapy alone (including intraoperative radiation
therapy – IORT) has not been shown to be of benefit over surgery alone.
Treatment of unresectable/ metastatic Disease (Stage IV)
Chemotherapy versus Best Supportive Care (49)
The results of studies and supportive evidence from recent trials
with palliative combination chemotherapy and best supportive care
indicate that patients with advanced incurable gastric cancer who are in
good performance status and can tolerate potential toxicities have a
modest benefit in survival, time to disease progression and quality of life
compared to best supportive care alone. Targeted therapies using the
vascular endothelial growth factor inhibitor Bevacizumab, epidermal
growth factor or tyrosine kinase inhibitors (cetuximab or geftinib
respectively) are showing exciting promise.
58
Surgery for Palliation
Since survival for patients with advanced gastric cancer is poor, any
proposed operation should provide sustained symptomatic relief while
minimizing morbidity and need for prolonged hospitalization. The
operative mortality for palliative surgery is about 25%, anastomotic
dehiscences accounting for a majority of deaths. Frequent symptoms for
which surgery is offered include obstruction, hemorrhage, pain, nausea
and dysphasia. A gastrojejunostomy palliates patients for a shorter
duration compared to a gastrectomy ( a mean of 5.9 months compared
with 14.6 months). Selection bias is likely to skew the results.
Radiation for Palliation
Radiation therapy, though used less frequently can be offered to
palliate pain or hemorrhage.
Long-Term Side Effects of Therapy
The long term consequences of therapy for gastric cancer include the
dumping syndromes, malabsorption and resulting weight loss, alkaline
reflux and late effects of chemotherapy or radiation therapy including
possible second malignancy. Dumping syndromes may occur in one of
the two forms –a): vasomotor causing diarrhea and cramping and
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palpitations (these can occur very shortly after a meal or 1 to 3 hours
later) and can be managed by adjusting the volume of oral intake and
other dietary manipulations and b): a reactive hypoglycemia that can
result from the rapid insulin release after a meal with little gastric
reservoir.
B12 malabsorption is well known resulting from a loss of intrinsic
factor. Iron and calcium malabsorption due to elimination of gastric acid
and may manifest many years later.
Failure patterns
Gastric cancers recur in multiple sites, both loco-regional and
systemic. Reported patterns of failure are somewhat variable.
In the report from MSKCC (50), 496 patients experienced
recurrences out of 1,038 patients who underwent R0 gastrectomy with D2
lymphadenectomy. Data on recurrence were available in 367 (74%)
patients. Multivariate analysis of the data revealed that female sex,
advanced T stage, and distal and diffuse type cancers were associated
with peritoneal recurrence while proximal tumours, early T stage, and
intestinal type tumors had association with locoregional recurrence.
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In another study from Korea, 508 patients developed recurrences out
of 2,038 patients treated with potentially curative gastrectomy (51) - 33%
involved locoregional sites, 44% were peritoneal, and 38% were distant.
It is therefore important to control both loco-regional disease as well as
systemic disease to improve long-term results.
Diagnostic Laparoscopy in staging carcinoma stomach
Diagnostic laparoscopy has emerged as an important tool in the
staging of gastrointestinal malignancies. It is used as an adjunct to other
conventional imaging modalities such as computed tomography (CT),
transabdominal ultrasound (USG), magnetic resonance imaging (MRI),
positron emission tomography (PET) in order to assess the presence and
extent of metastatic disease.
Indications
The common malignant conditions of the abdomen where diagnostic
laparoscopy is useful include esophageal carcinoma, gastric cancer,
pancreatic cancer, colorectal cancer and Gall bladder / cholangio
carcinoma. There have also been instances where patients with melanoma
of the trunk or extremities have had metastases to the small bowel,
causing unexplained gastrointestinal bleeding or small bowel obstruction.
These patients could also benefit from a diagnostic laparoscopy. Patients
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with Hodgkin lymphoma could also benefit from a staging laparoscopy to
assess and plan for the appropriate chemotherapy and/or radiation
therapy.
Indications for laparoscopic staging of abdominal tumors.
• Preoperative staging before major surgical resection
• Assessment of liver or lymph nodal status
• To Confirmation findings of CECT
• Therapeutic decision making for Hodgkin lymphoma
• Proper evaluation of ascitic fluid
The advantage of diagnostic laparoscopy over imaging techniques is
that it can not only help in direct visualization but also to biopsy
suspicious lesions on liver / peritoneal surface or lymph nodes and also to
perform peritoneal lavage. Imaging studies give only indirect evidence of
underlying disease.
In tropical countries where infectious diseases such as tuberculosis
or parasitic infestation are more common than cancer, laparoscopic
examination assists in the differential diagnosis of these entities.
Laparoscopy may aid in identification of adhesions as a cause of chronic
abdominal pain in patients with history of previous surgeries or with
chronic pelvic pain and an adhesiolysis may be beneficial in this group.
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Technique of Elective Diagnostic Laparoscopy
Following extensive preoperative diagnostic and staging work up,
patients are prepared for a diagnostic laparoscopy. Although, General
anesthesia is usually preferred for cancer staging, it can also done under
local anesthesia.
The operating table should be able to provide both Trendelenburg
and reverse Trendelenburg positions. Both upper and lower abdomen
should be completely examined by creating a pneumoperitoneum.
A midline supra- or sub- umbilical incision is made and a 10 mm
trocar introduced. The camera used is either a zero or 30- degree camera
for complete inspection. Additional 5 mm ports are introduced in right
and left upper quadrants for introducing grasping, dissecting or biopsy
forceps.
Biopsy may be performed with cupped forceps passed through either
a 5- or 10-mm trocar sleeve. Alternatively, cutting biopsy needles may be
used to obtain liver or nodal tissue (Fig. 19). The needle biopsy may be
performed percutaneously under laparoscopic guidance, or the biopsy
needle may be passed through one of the 5 mm trocar sheaths. It is
important to perform biopsy cleanly without crushing tissue, since this
might reduce the opportunity for pathologic review.
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Procedures performed during staging laparoscopy.
• Complete abdominal and pelvic inspection
• Division of gastro hepatic ligament
• Biopsy of suspicious liver or peritoneal nodules
• Peritoneal lavage for malignant cytology
• Ascitic fluid analysis for cytology
• Assessment and sampling of enlarged lymph nodes
• Laparoscopic ultrasonogram
64
Figure 19: The needle used for taking a liver biopsy can be introduced
either through a trocar or percutaneously.
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The areas required to be biopsied vary according to the location of
the primary cancer and its drainage areas. Lymph nodes are ideally
sampled intact in order to achieve good tissue architecture for HPE.
Though surgical resection might be required in most cases of
carcinoma stomach, be it for curative or palliative intent, diagnostic
laparoscopy may be useful in patients with unresectable and metastatic
disease wherein an unnecessary laparotomy can be avoided.
Diagnostic laparoscopy for the preoperative evaluation of gastric
carcinoma is done using three ports – a 10 mm umbilical port for the
camera and two working ports each 5 mm, if necessary, in each upper
quadrants.
1. The patient is placed in steep Trendelenburg position and the
assessment is commenced by inspection of the pelvic peritoneum to look
for minute peritoneal nodules, which become visible under magnification
of the laparoscope.
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Fig 20: Krukenberg tumour in a patient with Ca stomach
2. The operating table is then turned to a neutral position. The
table is rotated alternatively to right and left lateral positions (called “air-
planing” the table) in order to look for free fluid which, if present, is
aspirated and sent for cytological analysis.
3. The liver is then inspected by turning the table to head down
and left tilt. This position allows the liver to fall out of the
subdiaphragmatic space. A 45 degree angled scope is then used to
inspect all the visible surfaces of the liver. The liver is evaluated for
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suspicious nodules or adhesions or plaques, which are biopsied using
forceps or needle to look for metastases.
4. Any suspicious nodules on the peritoneal surface or omentum
are also biopsied with cupped forceps. Perfect hemostasis is achieved
using electrocautery.
Fig 21: Peritoneal nodule detected on staging laparoscopy
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5. This is followed by a complete examination of the anterior wall of
stomach.
Fig 22: Primory tumour breaching the anterior wall of stomach
6. The gastrohepatic omentum is divided to assess the status of
lymph nodes in the subhepatic region and along the lesser curvature.
These include the left gastric and celiac nodes.
7. The laparoscope is then introduced into the lesser sac for full
inspection
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The role of sentinel node biopsy in the preoperative staging of
gastric cancer is still under research and extensive studies are required to
prove its merits. There is evidence that lymph nodes involved in gastric
cancer are increasingly recognized by vital dyes and radionuclides. This
further emphasizes the potential role of sentinel node biopsy by staging
laparoscopy in carcinoma stomach.
The issue of timing and extent of laparoscopy is unresolved. When
performed as a separate procedure it has the disadvantage of the
additional risks and expense of a second general anesthetic. However,
separate procedure laparoscopy allows the additional staging information
acquired at laparoscopy (including the results of peritoneal cytology) to
be reviewed and discussed with the patient and multidisciplinary
treatment group prior to definitive treatment planning. Consequently, the
timing of laparoscopy varies in different centers depending on factors
such as the availability of intraoperative cytology assessment and the use





The objectives of the present study are
1. To determine the feasibility of using diagnostic laparoscopy as a
preoperative staging procedure in carcinoma stomach
2. To evaluate its superiority as a diagnostic tool in assessing
peritoneal and nodal metastasis.
3. To evaluate the role of staging laparoscopy in predicting the
accurate stage of disease and hence avoiding unnecessary exploratory
laparotomy
4. To assess the morbidity and mortality associated with or without






1. Setting : Department of General Surgery,
Government Stanley Hospital, Chennai
2. Study design : Non-Randomised Controlled Trial
3. Ethical Clearance : Obtained
4. Study period : 1 year
5. Materials : 40 patients of Carcinoma stomach
(23 male; 17 female)
6. Inclusion criteria : Patients with Carcinoma stomach proven
by OGD and Biopsy
7. Exclusion criteria : Patients unfit for any surgical procedure,




All patients diagnosed with carcinoma stomach by OGD scopy and
biopsy were stage grouped after USG and CECT abdomen and pelvis.
They were allocated into two groups of which one was subjected to a
Diagnostic Laparoscopy just before the definitive procedure while the
other was directly taken up for laparotomy based on imaging alone. The
staging laparoscopy included visualization of the primary tumour,
regional lymph nodes, liver, diaphragm and peritoneal surfaces and
biopsy of abnormal findings. The patients were then staged according to
the staging laparoscopy findings. For patients with evidence of
metastasis, the definitive procedure was abandoned. If these patients had
GOO, a feeding jejunostomy alone was done. For patients without
evidence of metastasis, definitive procedure was carried out. For the
second group, exploratory laparotomy was done and procedure performed
as per findings.





Table 4: Gender distribution
Gender D-lap group(n=20)
Laparotomy
group (n=20) p value
Male 12 (60%) 11 (55%)
1.00
























20-40 3 (15%) 4 (20%)
0.3940-60 11 (55%) 8 (40%)















D-lap group (n=20)Laparotomy group (n=20)
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Table 6: Site distribution
D-lap group (n=20) Laparotomy group (n=20)
Proximal gastric
cancer
8 (40%) 6 (30%)
Distal gastric
cancer
12 (60%) 14 (70%)











Proximal gastric cancerDistal gastric cancer
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A total of 40 patients with Carcinoma stomach diagnosed by Upper
GI endoscopy and confirmed by biopsy from the growth were enrolled in
the study. They were then staged according to CECT abdomen and
pelvis. Patients with evidence of metastasis by imaging were excluded
from the study. The rest were allocated into two groups – A Diagnostic
laparoscopy (D-Lap) group (12 males and 8 females) and a Laparotomy
group (11 males and 9 females) (Table 4).
Most of the patients in both groups, 17 (85%) in D-lap group and
16 (80%) in Laparotomy group, were above 40 years of age (Table 5).
However, both age and sex distributions were not statistically significant
(0.39 and 1.00 respectively).
On Upper GI endoscopy, 8 out of 20 (40%) in the D-lap group and
6 out of 20 (30%) in the laparotomy group were proximal gastric cancers
while the rest were distal gastric cancers (Table 6). The site distribution
of gastric cancer was also not statistically significant. All the cases in
both the groups proved to be adenocarcinoma on histopathological
examination of the biopsy from the growth.
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Of the 20 patients who underwent diagnostic laparoscopy, 4 of
them (20%) proved to have metastasis and hence definitive procedure
was abandoned. Feeding jejunostomy (FJ) alone was done in two of them
who had GOO while for the other two (10%) who did not have
obstruction, laparotomy was avoided and were directly referred for
palliative chemotherapy. Of the remaining 16 patients who did not have
evidence of metastasis, 3 had posterior fixity for which Anterior
Gastrojejunostomy (AGJ) alone was done and 13 had resectable tumours
for which Total gastrectomy (TG) with Roux-en-Y esophago-
jejunostomy was done in 6 patients and subtotal gastrectomy (STG) with
Roux-en-Y GastroJejunostomy was done in 7 patients.
Of the 20 patients in the laparotomy group, 2 (10%) had evidence
of peritoneal / liver metastasis for whom FJ alone was done. Of the rest of
the 18 patients who did not have metastatic disease, 5 had unresectable
tumours for which AGJ was done in 4 of them and FJ was done one
patient. 13 had resectable tumours for which Total gastrectomy was done
in 3 patients and Subtotal gastrectomy was done in 10 patients. Although
Staging laparoscopy resulted in higher detection of metastasis in patients
with carcinoma stomach (20% vs 10%), it was not statistically significant
(p = 0.66). But this could be explained by the small sample size.
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The postoperative complications (table 9) included surgical site
infections in 4 patients in each group, Wound dehiscence in one patient in
D-lap group and two patients in the laparotomy group all of which were
conservatively managed. Anastomotic leak occurred in one patient in D-
lap group, which was conservatively managed, and in two patients in the
laparotomy group of which one settled conservatively while the other
went for sepsis and eventually death. The incidence of immediate
postoperative complications was comparable in both groups of patients
and the difference it was not statistically significant (p=1.00).
Only one patient (5%) in the D-lap group who had no metastasis
but unresectable tumour succumbed eventually in the postoperative
period due to cardiac complications. In the laparotomy group, four (20%)
patients (two with metastasis and two without metastasis) eventually
succumbed. There was no mortality in any of the four patients with
metastasis detected by staging laparoscopy whereas both patients with
metastasis who underwent laparotomy eventually died. This could be
explained by the change in treatment plan according to the accurate
staging by laparoscopy in these patients. However, this difference was
not statistically significant (p=0.34) again due to the small sample size.
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LIMITATIONS
1. The study is done only in a small number of patients.
2. Since all patients had the diagnostic laparoscopy just prior to the
definitive surgery, we could not compare the effect of diagnostic
laparoscopy when done as a separate procedure.
3. Only direct visualization of the tumour, peritoneal and liver
surfaces and diaphragm was done as part of the procedure.
Assessment of lymph nodes along celiac axis and left gastric artery
by division of gastrohepatic omentum and gastro colic omentum
could not be done due to technical constraints.
4. The role of laparoscopic ultrasound and role of tumour markers in





Diagnostic laparoscopy in patients with carcinoma stomach without
evidence of metastasis by conventional imaging has resulted in detection
of peritoneal metastasis in 20% (4 out of 20) of the cases and hence
upstaging of disease and a change in treatment plan in all of them and
also avoidance of unnecessary laparotomy in 10% (2 out of 20) cases.
Moreover, the postoperative complications in the D-lap group
without metastasis were comparable to and not significantly higher than
those in the control group making it a safe procedure. Hence, a routine
diagnostic laparoscopy is advocated for all patients of carcinoma stomach







Diagnostic laparoscopy has been advocated as a way of improving
staging in carcinoma stomach by detecting low volume liver surface and
peritoneal metastasis which are usually missed by conventional imaging,
thereby protecting the patient from an unnecessary laparotomy.
AIMS AND OBJECTIVES:
The present study was undertaken to ascertain the feasibility of
using diagnostic laparoscopy as a routine staging investigation in patients
with carcinoma stomach and to evaluate its superiority over conventional
imaging modalities in detecting peritoneal and liver surface metastasis
and to assess the morbidity and mortality associated with or without its
use.
MATERIALS AND METHODS:
The study is a non-randomised controlled trial wherein 40 patients
with carcinoma stomach proven by OGD and biopsy with no evidence of
metastasis on CECT abdomen and pelvis were allocated into two groups.
One group of 20 patients had a diagnostic laparoscopy done just before
the definitive procedure while the other group did not.
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RESULTS AND DISCUSSION:
Of the 20 patients in the diagnostic laparoscopy group, peritoneal
metastasis were detected in 20% (4 out of 20), hence resulting in
upstaging of disease and a change in treatment plan in all of them and
also avoidance of unnecessary laparotomy in 10% (2 out of 20) cases.
Moreover, the postoperative complications in the D-lap group
without metastasis including wound infection, wound dehiscence,
anastomotic leak, DVT were comparable to and not significantly higher
than those in the control group making it a safe procedure to perform.
CONCLUSION:
Hence, a routine diagnostic laparoscopy is advocated for all patients
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Patient Information ModuleYou are being invited to be a subject in this study.Before you participate in this study, I am giving you the following details aboutthis trial, which includes the aims, methodology, intervention, possible side effects, ifany and outcomes:All patients diagnosed with carcinoma stomach by OGD scopy and biopsy will beincluded in this study. A detailed clinical history will be taken following a standardizedproforma. A detailed clinical examination will be made and relevant investigations,including basic and special investigations will be done and stage grouping will be doneafter USG and CECT abdomen and pelvis. Patients will be allocated into two groups ofwhich one will be subjected to a Diagnostic Laparoscopy which includes directvisualization and biopsy of abnormal findings on the peritoneal and liver surfaces andentry into the lesser sac by dividing the gastrohepatic ligament which will allowassessment of lymph nodes adjacent to the lesser curve and celiac axis (lymph nodestations 16–20). The patients will then be staged according to the staging laparoscopyfindings. A pathological staging will also be obtained after the definitive procedure andhistopathological examination of the specimen. Tumor markers CEA, CA 125 will also bedone for patients in the staging laparoscopy group to look for their correlation withmetastatic disease.The results arising from this study will be analyzed and used for academicpurposes. You will be given clear instructions at every step and you are free to ask/clarify any doubts. Your identity will remain confidential. You are free to withdraw fromthis trial at any point of time, without any prior notice &/ or without any medical orlegal implications.I request you to volunteer for this study.Thanking You,
Investigator’s Sign Patient’s Sign(Dr. M. Srinivasan) (Name:
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Informed ConsentName: Age/ Sex: IP:
I herewith declare that I have been explained in a language fully understood
by me regarding the purpose of this study, methodology, proposed intervention,
plausible side effects, if any and sequelae.
I have been given an opportunity to discuss my doubts and I have received the
appropriate explanation.
I understand that my participation in this study is completely voluntary and
that I am free to withdraw from this study at anytime without any prior notice &/ or
without having my medical or legal rights affected.
I permit the author and the research team full access to all my records at any
point, even if I have withdrawn from the study. However my identity will not be
revealed to any third party or publication.
I herewith permit the author and the research team to use the results and
conclusions arising from this study for any academic purpose, including but not
limited to dissertation/ thesis or publication or presentation in any level.
Therefore, in my full conscience, I give consent to be included in the study
and to undergo any investigation or any intervention therein.
Patient’s Sign Investigator’s Sign
(Dr. M. Srinivasan)
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CASES - STAGING / DIAGNOSTIC LAPAROSCOPY GROUP





1 SARANGAN 24 M PROXIMAL ADENO NO METS TG SSI
2 MARI 38 M DISTAL ADENO NO METS STG
3 MURUGAN 44 M PROXIMAL ADENO NO METS TG ANAST LEAK
4 NAZIR HUSSAIN 45 M DISTAL ADENO METS FJ
5 PANDIAN 47 M DISTAL ADENO NO METS STG
6 RAMAN 55 M PROXIMAL ADENO NO METS TG
7 VISHWANATHAN 58 M DISTAL ADENO UNRESECTABLE AGJ SSI
8 MANIKANDAN 52 M DISTAL ADENO UNRESECTABLE AGJ
9 DURAIRAJ 62 M PROXIMAL ADENO METS NONE
10 SANIAPPAN 65 M DISTAL ADENO NO METS STG SSI
11 APPADURAI 60 M DISTAL ADENO NO METS STG
12 VALLI 35 F PROXIMAL ADENO METS NONE
13 VIMALA 53 F DISTAL ADENO UNRESECTABLE AGJ
14 SELSA 55 F PROXIMAL ADENO NO METS TG DEATH
15 PUSHPA 45 F DISTAL ADENO NO METS STG
16 SAROJA 48 F DISTAL ADENO NO METS STG SSI
17 SELVI 28 F PROXIMAL ADENO NO METS TG WD
18 LAKSHMI 63 F DISTAL ADENO NO METS STG
19 RANI 65 F DISTAL ADENO METS FJ
20 CHELLATHAI 68 F PROXIMAL ADENO NO METS TG
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METS - METASTASIS AGJ - ANTERIOR GASTROJEJUNOSTOMY
TG - TOTAL GASTRECTOMY ANAST LEAK - ANASTOMOTIC LEAK
STG - SUBTOTAL GASTRECTOMY SSI - SURGICAL SITE INFECTION
FJ - FEEDING JEJUNOSTOMY WD - WOUND DEHISCENCE
CONTROL - LAPAROTOMY GROUP





1 LOGANATHAN 25 M PROXIMAL ADENO NO METS TG ANAST LEAK
2 DHANAPAL 35 M DISTAL ADENO NO METS STG SSI
3 GOUSE BASHA 44 M DISTAL ADENO NO METS STG
4 MANAIAH 54 M DISTAL ADENO METS FJ DEATH
5 ARUMUGAM 56 M PROXIMAL ADENO NO METS TG SSI
6 MOHAN 58 M DISTAL ADENO UNRESECTABLE AGJ WD
7 GANESAN 60 M DISTAL ADENO NO METS STG
8 RANGARAJ 72 M PROXIMAL ADENO UNRESECTABLE FJ DEATH
9 VARADHAN 68 M DISTAL ADENO UNRESECTABLE AGJ SSI
10 MUNUSAMY 65 M DISTAL ADENO NO METS STG
11 GOVINDSAMY 62 M DISTAL ADENO NO METS STG
12 PREMA 35 F DISTAL ADENO NO METS STG SSI
13 KALA 38 F PROXIMAL ADENO METS FJ DEATH
14 JAYALAKSHMI 45 F DISTAL ADENO UNRESECTABLE AGJ
15 THULASI 49 F DISTAL ADENO NO METS STG WD
109
16 SHANTHI 55 F DISTAL ADENO NO METS STG
17 PANJALI 58 F PROXIMAL ADENO NO METS TG ANAST LEAK DEATH
18 JANAKI 62 F DISTAL ADENO UNRESECTABLE AGJ
19 KANNAMMAL 65 F DISTAL ADENO NO METS STG
20 RUKMANI 66 F PROXIMAL ADENO NO METS TG
